AlidaBio has launched the EpiPlex Duo-Mod Service, a turnkey offering that maps and quantifies m6A and inosine RNA modifications alongside RNA expression in a single integrated report. The service is designed for researchers who need sensitive RNA modification detection, relative quantitation and RNA-seq data from clinical samples, including fresh frozen tissue and FFPE tissue.

The EpiPlex Duo-Mod Service applies AlidaBio's proximity barcoding and enrichment chemistry to profile m6A, inosine and gene expression from the same RNA input. This analysis enables researchers to identify genes with matched expression yet divergent modification states, assess coordinated shifts across modification types, and examine how modification stoichiometry relates to transcriptional changes. All results are delivered through an EpiScout HTML report that includes publication-quality figures, along with FASTQ, BAM, BED, tsv and vcf files for downstream analysis.

"By combining multi-mod detection with RNA expression in one workflow, the EpiPlex Duo-Mod Service makes it much easier for scientists to interpret how the epitranscriptome shapes functional outcomes, since RNA modifications capture regulatory events, such as altered stability, translation efficiency, or RNA localisation, that cannot be inferred from expression levels alone. Our goal is to give researchers the clearest possible picture from the smallest possible amount of RNA, with robust quantitation powered by our spike-in standards and EpiScout analysis," said Dr Gudrun Stengel, CEO, AlidaBio. 

Early-access users report accelerated discovery and improved interpretability of RNA modification data.

"Collaborating with AlidaBio's RNA modification profiling service helped us rapidly generate, interpret and visualise epitranscriptomic data in a way that strengthened our mechanistic story and supported our Frontiers in Genetics publication. EpiPlex has been an invaluable platform for advancing our research," said Dr Akira Sassa, Associate Professor, Graduate School of Science, Chiba University.

His group studies the connection between RNA editing and DNA repair.

"Making robust, transcriptome-wide RNA modification profiling available as a service has the potential to lower the barrier for many labs, helping to accelerate discoveries and broaden the impact of epitranscriptomics across different areas of biology. The support we have received from the AlidaBio team so far has been really valuable for our projects," according to Dr Ina Anreiter, Assistant Professor—Department of Biological Sciences, University of Toronto.

Dr Anreiter is interested in the epitranscriptomic regulation of behaviour, stress response and biological embedding.

"AlidaBio's RNA modification profiling service provided rapid, high-quality epitranscriptomic data that we could readily integrate with our other datasets, helping us refine our understanding of how targeted therapies can influence ageing-related pathways in the brain," said Eloy Santos-Pujol—Cancer Epigenetics Group, Josep Carreras Leukemia Research Institute.

Large-scale studies continue to underscore the translational potential of RNA modifications. For example, in a recent comprehensive survey of 162 localised primary prostate tumours, Xin Xu et al (Nat Genet. 2025 Apr;57(4):934-948) showed that global and locus-specific m6A patterns correlate with tumour aggression, progression risk and patient outcomes, suggesting m6A as a prognostic biomarker for prostate cancer.

"To move into the clinic, we need sensitive and robust m6A assays. We tested AlidaBio's EpiPlex assay, and it appears to excel at both," said the study's corresponding co-author Dr Hansen He, Professor—Department of Medical Biophysics, University of Toronto and Senior Scientist, Princess Margaret Cancer Centre, University Health Network.

The EpiPlex Duo-Mod Service supports m6A and inosine mapping from as little as 20 ng mRNA or 250 ng total RNA and accepts human, mouse and rat samples, with additional species available upon request. AlidaBio performs the complete workflow, from RNA extraction and library preparation through sequencing and data processing, ensuring consistency across projects. Additional custom bioinformatics analysis is available upon request. Standard turnaround time is six to eight weeks, with an expedited four-week option.